Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Hexner

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|June 7, 2014
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutationElizabeth Hexner, Gail Roboz, Ron Hoffman, et al.
Biomarker Research|July 26, 2016
Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case reportMargaret Lewen, Renee Gresh, Maria Queenan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2014
Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in miceQing Tong, Shan He, Fang Xie, et al.
Blood|January 18, 2007
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cellsJiang Zhu, Russell Garrett, Younghun Jung, et al.
American Journal of Hematology|January 29, 2016
Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLIAnita J Kumar, Pavel Vassilev, Alison W Loren, et al.
British Journal of Haematology|May 17, 2018
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology GroupJason Aynardi, Rashmi Manur, Paul R Hess, et al.
American Journal of Hematology|September 27, 2008
Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormalityNoelle V Frey, Christopher E Leid, Peter C Nowell, et al.
The Journal of Pediatrics|August 1, 2009
Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation updateAnke K Bergmann, Inderneel Sahai, Jill F Falcone, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Blood|November 9, 2011
The cell cycle regulator CDC25A is a target for JAK2V617F oncogeneEmilie-Fleur Gautier, Muriel Picard, Camille Laurent, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|June 7, 2014
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutationElizabeth Hexner, Gail Roboz, Ron Hoffman, et al.
Biomarker Research|July 26, 2016
Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case reportMargaret Lewen, Renee Gresh, Maria Queenan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2014
Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in miceQing Tong, Shan He, Fang Xie, et al.
Blood|January 18, 2007
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cellsJiang Zhu, Russell Garrett, Younghun Jung, et al.
American Journal of Hematology|January 29, 2016
Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLIAnita J Kumar, Pavel Vassilev, Alison W Loren, et al.
British Journal of Haematology|May 17, 2018
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology GroupJason Aynardi, Rashmi Manur, Paul R Hess, et al.
American Journal of Hematology|September 27, 2008
Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormalityNoelle V Frey, Christopher E Leid, Peter C Nowell, et al.
The Journal of Pediatrics|August 1, 2009
Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation updateAnke K Bergmann, Inderneel Sahai, Jill F Falcone, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Blood|November 9, 2011
The cell cycle regulator CDC25A is a target for JAK2V617F oncogeneEmilie-Fleur Gautier, Muriel Picard, Camille Laurent, et al.
Pageof 6